On March 15, 2021 Peptomyc reported that the company has reached another major milestone obtaining the approval from the Spanish authorities (AEMPS) to initiate the First in Human Phase I/II trial with its first compound OMO-103 in patients with advanced solid tumors (Press release, Peptomyc, MAR 15, 2021, View Source [SID1234576695]). Peptomyc will soon start treating the first patients with this disruptive Myc inhibitor in selected clinical sites in Barcelona and Madrid. The company could achieve this key milestone thanks to an outstanding team, great collaborators and consultants.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Chief Medical Officer of Peptomyc, Manuela Niewel, MD, PhD, comments: "Now we will be able to translate the good preclinical results into hopefully great benefit for the patients".